Matinas BioPharma Holdings, Inc. 8-K

What Happened
Matinas BioPharma Holdings, Inc. (MTNB) filed an 8-K reporting that Chief Financial Officer Keith Kucinski notified the company on November 18, 2025 that he would resign as CFO effective January 17, 2026 to pursue other opportunities. On January 22, 2026 the board appointed Jerome D. Jabbour — the company’s Chairman, President and CEO — as interim Chief Financial Officer. Mr. Jabbour will continue his roles as Chairman, President and CEO while assuming the duties of the company’s principal financial officer and principal accounting officer until a successor is appointed or he resigns/removed.

Key Details

• CFO Keith Kucinski’s resignation effective date: January 17, 2026 (notice given Nov 18, 2025).
• Interim appointment effective date: Jerome D. Jabbour appointed interim CFO on January 22, 2026.
• Mr. Jabbour will retain his Chairman, President and CEO roles while acting as principal financial and accounting officer.
• The company says Mr. Jabbour’s compensatory and other material employment terms remain unchanged; there are no special arrangements or related-person transactions disclosed.

Why It Matters
This change centralizes executive and financial responsibilities in the company’s existing CEO on an interim basis, which maintains leadership continuity but temporarily combines CEO and CFO duties. The filing indicates no immediate change in compensation or disclosed conflicts, and the company will operate with Mr. Jabbour as the principal financial and accounting officer until a permanent CFO is named. Investors should note the leadership change for governance and financial reporting oversight, and watch for future updates about a permanent CFO appointment.